I’m a product description. I’m a great place to add more details about your product such as sizing, material, care instructions and cleaning instructions.
$78.00
A triple agonist targeting GLP-1, GIP, and glucagon receptors, is under investigation in preclinical and clinical research for its potential to enhance insulin secretion, suppress appetite, increase energy expenditure, and reduce body weight and liver fat in animal models and human trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease.
Store in a cool, dark place or freeze at -20°C for long term storage. Refrigerate after reconstitution
Product Name: Reta
CAS: 2381089-83-2
Molecular Mass: 4731.33 g/mol
Molecular Formula: C223H343F3N46O70
Glp-3RT is an investigational synthetic peptide, a triple agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors, exerting synergistic effects on energy homeostasis and glucose regulation through enhanced insulin secretion, appetite suppression via central nervous system signaling, delayed gastric emptying, increased energy expenditure, and promotion of lipolysis and fatty acid oxidation in preclinical models and early clinical studies. In phase 2 trials involving adults with obesity or type 2 diabetes, retatrutide administered subcutaneously once weekly demonstrated dose-dependent reductions in body weight (up to 24.2% at 12 mg over 48 weeks), improvements in glycemic control (e.g., HbA1c reductions), and decreases in liver fat content (up to 82% in metabolic dysfunction-associated steatotic liver disease cohorts), with a safety profile characterized primarily by gastrointestinal adverse events similar to other incretin mimetics, though long-term efficacy and safety data from ongoing phase 3 trials remain pending.
All items available on this website are intended exclusively for research and development purposes, including laboratory and analytical applications, and are not meant for human or animal consumption in any form. The products are not designed to diagnose, treat, cure, or prevent any medical conditions, and their associated claims have not been reviewed or approved by the U.S. Food and Drug Administration. Purus Peptides operates solely as a supplier of research chemicals and is neither a compounding pharmacy nor an outsourcing facility as defined by sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act
All products are sold in powder (lyophilized) form and require reconstitution with a suitable dilutant for research purposes only. Research supplies (e.g., syringes, bacteriostatic water) are not included. No dosing instructions are provided. We adhere to all local and state laws around Research Only Chemical sales. We are not a pharmacy, nor do we promote or provide any advice for human or animal consumption. Please review our terms and conditions carefully before making a purchase on our website.
By clicking ”I Agree” you confirm that you have read and accepted the Terms and Conditions stated above.
